Novo Nordisk ® mg has demonstrated an impact th obesity n the United States ATES ONLY T2D ~35m 10m 6m <0.5m 0.5m 0.5m 1m 0.5m 5m 0.5m HFpEF/HFmrEF ~4m Obesity-related comorbidities SELECT trial Myocardia l Stroke † infarcti 2 o 0 n % † MACE risk reduction STEP HFpEF trial Heart failure KCCQ-CSS score ETD: 7.8 (semaglutide 2.4 mg vs placebo) Knee osteoarthritis trial Hypertens ion 41.7 WOMAC pain score reduction rotic cardiovascular disease; MACE: Major adverse cardiovascular events; ETD: Estimated treatment difference; HFpEF: rio and McMaster University Osteoarthritis index. Note: Prevalence overlaps are estimated on patient-level data from s. Numbers are rounded betes Federation: Diabetes Atlas 10 th edition, 2021; World Obesity Atlas 2023
Download PDF file